Fowke KR, Nagelkerke NJ, Kimani J, et al. Resistance to HIV-1 infection among persistently seronegative prostitutes in Nairobi, Kenya. Lancet 1996;348:1347–1351.
Rowland-Jones S, Sutton J, Ariyoshi K, et al. HIV-specific cytotoxic T-cells in HIV-exposed but uninfected Gambian women. Nat Med 1995;1:59–64.
Wagner R, Leschonsky B, Harrer E, et al. Molecular and functional analysis of a conserved CTL epitope in HIV-1 p24 recognized from a long-term nonprogressor: Constraints on immune escape associated with target-ing a sequence essential for viral replication. J Immunol 1999;162:3727–3734.
Prince AM, Reesink H, Pascual D, et al. Prevention of HIV infection by passive immunization with HIV im-munoglobuline. AIDS Res Hum Retroviruses 1991;7: 971–973.
Putkonen P, Thorstensson R, Ghavamzadeh L, et al. Prevention of HIV-2 and SIVsm infection by passive immunization in cynomolgus monkeys. Nature 1991; 352:436–438.
Emini EA, Schleif WA, Nunberg JH, et al. Prevention of HIV-1 infection in chimpanzees by gp120 V3 domain-speci c monoclonal antibody. Nature 1992; 355:728–730.
Mascola JR, Lewis MG, Stiegler G, et al. Protection of macaques against pathogenic simian/human immunodeficiency virus 89. 6PD by passive transfer of neutralizing antibodies. J Virol 1999;73:4009–4018.
Barouch DH, Santra S, Schmitz JE, et al. Control of viremia and prevention of clinical AIDS in rhesus monkeys by cytokine-augmented DNA vaccination. Science 2000;290:486–492.
Amara RR, Villinger F, Altman JD, et al. Control of a mucosal challenge and prevention of AIDS by a mul-tiprotein DNA/MVA vaccine. Science 2001;292: 69–74.
Shiver JW, Fu T, Chen L, et al. Replication-incompe-tent adenoviral vaccine vector elicits effective anti-immunodeficiency-virus immunity. Nature 2002;415: 331–335.
Barouch DH, Kunstman J, Kuroda MJ, et al. Eventual AIDS vaccine failure in a rhesus monkey by viral escape from cytotoxic T lymphocytes. Nature 2002; 415:335–339.
Parren PW, Burton DR, Sattentau QJ. HIV-1 antibody –debris or virion? Nat Med 1997;3:366–367.
Moore JP, Cao Y, Qing L, et al. Primary isolates of human immunode ciency virus type 1 are relatively resistant to neutralization by monoclonal antibodies to gp120, and their neutralization is not predicted by studies with monomeric gp120. J Virol 1995;69:101–109.
Parren PW, Moore JP, Burton DR, et al. The neutralizing antibody response to HIV-1:Viral evasion and escape from humoral immunity. AIDS 1999;13:S137–162.
Chackerian B, Rudensey LM, Overbaugh J. Specific N-linked and O-linked glycosylation modi cations in the envelope V1 domain of simian immunodeficiency virus variants that evolve in the host alter recognitionby neutralizing antibodies. J Virol 1997;71:7719–7727.
Wei X, Decker JM, Wang S, et al. Antibody neutralization and escape by HIV-1. Nature 2003;422: 307–312.
Borrow P, Lewicki H, Hahn BH, et al. Virus-speci c CD8+cytolytic T-lymphocyte activity associated with control of viremia in primary human immunodeficiency virus type 1 infection. J Virol 1994;68:6103–6110.
Schmitz JE, Kuroda MJ, Santra S, et al. Control of viremia in simian immunodeficiency virus infection by CD8+lymphocytes. Science 1999;283:857–860.
Cao Y, Qin L, Zhang L, et al. Virologic and immunologic characterization of long-term survivors of human immunodeficiency virus type 1 infection. New Engl J Med 1995;332:201–208.
Ballegooijen van M, Bogaards JA, Weverling GJ, et al. AIDS vaccines that allow HIV-1 to infect and escape immunologic control:A mathematic analysis of mass vaccination. J Acq Immun Def Synd 2003;34:214–220.
Goulder PJ, Brander C, Tang Y, et al. Evolution and transmission of stable CTL escape mutations in HIV infection. Nature 2001;412:334–338.
Koenig S, Conley AJ, Brewah YA, et al. Transfer of HIV-1-speci c cytotoxic T lymphocytes to an AIDS patient leads to selection for mutant HIV variants and sub-sequent disease progression. Nat Med 1995;1:330–336.
Price DA, Goulder PJ, Klenerman P, et al. Positive selection of HIV-1cytotoxic T lymphocyte escape variants during primary infection. Proc Natl Acad Sci USA 1997;94:1890–1895.
Rosenberg ES, Billingsley JM, Caliendo AM, et al. Vigorous HIV-1-specific CD4+T cell responses asso-ciated with control of viremia. Science 1997;278:1447–1450.
McMichael AJ, Rowland-Jones SL. Cellular immune responses to HIV. Nature 2001;410:980–987.
Cohen J. AIDS vaccine trial produces disappointment and confusion. Science 2003;299:1290–1291.
Baalen van CA, Pontesilli O, Huisman RC, et al. Human immunode ciency virus type 1 Rev-and Tat-speci c cytotoxic T lymphocyte frequencies inversely correlate with rapid progression to AIDS. J Gen Virol 1997;78:1913–1918.
Pontesilli O, Klein MR, Kerkhof-Garde SR, et al. Longitudinal analysis of human immunode ciency virus type 1-speci c cytotoxic T lymphocyte responses: A predominant gag-speci c response is associated with nonprogressive infection. J Infect Dis 1998;178:1008–1018.
Klein MR, Baalen van CA, Holwerda AM, et al. Kinetics of Gag-specific cytotoxic T lymphocyte responses during the clinical course of HIV-1 infection: A longitudinal analysis of rapid progressors and long-term asymptomatics. J Exp Med 1995;181:1365–1372.
Seth A, Ourmanov I, Schmitz JE, et al. Immunization with a modi ed vaccinia virus expressing simian immunodeficiency virus (SIV)Gag-Pol primes for an anamnestic Gag-speci c cytotoxic T-lymphocyte response and is associated with reduction of viremia after SIV challenge. J Virol 2000;74:2502–2509.
Abimiku AG, Robert-Guro. M, Benson J, et al. Long-term survival of SIVmac251-infected macaques previ-ously immunized with NYVAC-SIV vaccines. J Acq Immun Def Synd 1997;15:S78–S85.
Barouch DH, Santra S, Kuroda MJ, et al. Reduction of simian-human immunode ciency virus 89.6P viremia in rhesus monkeys by recombinant modified vaccinia virus Ankara vaccination. J Virol 2001;75: 5151–5158.
Kent SJ, Zhao A, Best SJ, et al. Enhanced T-cell immunogenicity and protective efficacy of a human immunode ciency virus type 1 vaccine regimen consisting of consecutive priming with DNA and boosting with recombinant fowlpox virus. J Virol 1998;72: 10180–10188.
Hammond SA, Bollinger RC, Stanhope PE, et al. Comparative clonal analysis of human immunodeciency virus type 1 (HIV-1)-specific CD4+and CD8+ cytotoxic T lymphocytes isolated from seronegative humans immunized with candidate HIV-1 vaccines. J Exp Med 1992;176:1531–1542.
Evans TG, Keefer MC, Weinhold KJ, et al. A canarypox vaccine expressing multiple HIV-1 genes given alone or with rgp120 elicits broad and durable CD8+CTL responses in seronegative volunteers. J Infect Dis 1999;180:290–298.
Belshe RB, Stevens C, Gorse GJ, et al. Safety and immunogenicity of a canarypox-vectored human immunode ciency virus type 1 vaccine with or without gp120:A phase 2 study in higher and lower-risk volunteers. J Infect Dis 2001;183:1343–1352.
Sullivan NJ, Sanchez A, Rollin PE, et al. Development of a preventive vaccine for Ebola virus infection in primates. Nature 2000;30:605–609.
Casimiro DR, Chen L, Fu TM, et al. Comparative immunogenicity in rhesus monkeys of DNA plasmid, recombinant vaccinia virus, and replication-defective adenovirus vectors expressing a human immunodeficiency virus type 1 gag gene. J Virol 2003;77:6305–6313.
Farina SF, Gao GP, Xiang ZQ, et al. Replication-defective vector based on a chimpanzee adenovirus. J Virol 2001;75:11603–11613.
Vogels R, Zuijdgeest D, Rijnsoever van R, et al. Replication-deficient human adenovirus type 35 vectors for gene transfer and vaccination:Eficient human cell interaction and bypass of preexisting adenovirus immunity. J Virol 2003;77:8263–8271.
Shiver JW, Emini EA. Recent advances in the development of HIV-1 vaccines using replication-incompe-tent adenovirus vectors. Annu Rev Med 2004;55: 355–372.
Mossman SP, Bex F, Berglund P, et al. Protection against lethal simian immunode ciency virus SIV-smmPBj14 disease by a recombinant Semliki Forest virus gp160 vaccine and by a gp120 subunit vaccine. J Virol 1996;70:1953–1960.
Davis NL, Caley IJ, Brown KW, et al. Vaccination of macaques against pathogenic simian immunode ciency virus with Venezuelan equine encephalitis virus replicon particles. J Virol 2000;74:371–378.